Santaris Raises $12M in Private Investment Round | GenomeWeb

Santaris Pharma this week announced that it has raised $12 million through the sale of convertible bonds to existing private investors and members of the company's management.

Santaris said that proceeds from the financing would primarily be used to fund the continued development of its microRNA-targeting hepatitis C drug miravirsen, which is under phase II development, as well as its pipeline of other locked nucleic acid-based therapeutic candidates.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.